StatStrip Gen 2.0 glucose meter Class I correction: interim safeguards until the software update
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · High priority
FDA identified Nova Biomedical's correction of its StatStrip Glucose Hospital Meter System as the most serious type of recall (Class I): on the Gen 2.0 model only, prior patient or quality-control information may remain on the meter screen when a barcode is scanned and, if accepted, assign a glucose result to the wrong patient. FDA issued its communication on October 20, 2026 and updated it on October 30 to clarify the recommended actions. Nova intends to roll out a software update in November 2026 in a phased manner; until then users follow updated instructions or, if an alternative meter is available, stop using the affected meter.
Current status
On November 10, 2026, the FDA page showed content current as of October 30, 2026, the date FDA updated it to clarify the recommended actions. It told users with an alternative meter to stop using the affected meter until it is updated; users without one must continue the mitigation steps, including checking after every barcode scan that the patient ID displayed is for the patient being tested, until the software fix becomes available.
Who this affects
Hospitals using Nova Biomedical StatStrip Gen 2.0 glucose hospital meters
Why it matters
A glucose result assigned to the wrong patient can lead clinicians to act on another patient's value; FDA's page says this could mean delayed treatment, unnecessary treatment (including inappropriate insulin administration) or failure to treat the intended patient, and that critically ill patients and infants are at greater risk. Until the software update reaches a hospital's meters, units without an alternative meter depend on the manufacturer's mitigation steps, including staff checking the patient identification after every barcode scan and again on the result screen.
Recommended action
- If an alternative meter is available, stop using the affected StatStrip meter until it is updated (FDA recommendation)
- Otherwise follow the manufacturer's interim safeguards, including patient identification checks
- Identify affected models, review FDA's current instructions and confirm mitigation and software-update plans
Scope and timing
- Authority status
- Other (FDA Class I recall correction communication)
- Responsible owner
- Clinical operations, Laboratory (point-of-care testing), Biomedical engineering, Patient safety
- Publication date
- 2026-10-20
- Other dates
- 2026-10-30 FDA update; the FDA page says Nova intends to roll out the software update in November 2026, in phases (no exact date)
Not established
Manufacturer letters not retained.
Earlier article: November 4, 2026 edition →
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →